|
A Study of BMY-27857 in Patients with AIDS or AIDS Related Complex Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on A Study of BMY-27857 in Patients with AIDS or AIDS Related Complex conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Study of BMY-27857 in Patients with AIDS or AIDS Related Complex Clinical research trials and A Study of BMY-27857 in Patients with AIDS or AIDS Related Complex medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like A Study of BMY-27857 in Patients with AIDS or AIDS Related Complex. A Study of BMY-27857 in Patients with AIDS or AIDS Related Complex Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a A Study of BMY-27857 in Patients with AIDS or AIDS Related Complex clinical trial. Participants frequently obtain the most expert healthcare available for their A Study of BMY-27857 in Patients with AIDS or AIDS Related Complex condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of BMY-27857 in Patients with AIDS or AIDS Related Complex  A Study of BMY-27857 in Patients with AIDS or AIDS Related Complex
A Study of BMY-27857 in Patients with AIDS or AIDS Related Complex
For Condition: HIV Infections
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) , Bristol-Myers Squibb
Synopsis: To evaluate the safety, minimum effective dose (MED), pharmacokinetics and efficacy of orally administered 2',3'-dideoxy-2',3'-didehydrothymidine (d4T) in patients with AIDS or AIDS related complex (ARC). To establish an appropriate dosage regimen of d4T to be employed in Phase II and III trials. To evaluate the effects of de-escalating doses of d4T on markers associated with HIV infection. Currently, the only FDA-approved therapy for patients with AIDS or ARC is zidovudine (AZT), a drug with significant value but limited use because of toxic effects on the bone marrow. d4T has not been tested in humans, but it has inhibited the reproduction of HIV (the virus that causes AIDS) in laboratory experiments. In some studies with laboratory animals, d4T was less toxic against blood cells than AZT.
Details: Currently, the only FDA-approved therapy for patients with AIDS or ARC is zidovudine (AZT), a drug with significant value but limited use because of toxic effects on the bone marrow. d4T has not been tested in humans, but it has inhibited the reproduction of HIV (the virus that causes AIDS) in laboratory experiments. In some studies with laboratory animals, d4T was less toxic against blood cells than AZT. A maximum tolerated dose (MTD) has been found in Phase I trials to date. An MED will be determined. The daily dose of d4T is divided into 2 portions and administered approximately 12 hours apart for 10 weeks. 5 patients receive the initial dose level and successive groups of 5 patients enter the study at a lower dose level once 3 patients in the preceding group have successfully completed at least 3 weeks of dosing and shown a positive effect on CD4 cell count and p24 antigen levels. The initial group of patients continue dosing at their dose level for an additional 94 weeks as long as they are doing well as measured by p24 antigen levels and CD4 cell counts. The dose de-escalation scheme continues until a lack of efficacy is seen in 2 of 5 patients in any group. Patients are assigned to de-escalating dose level treatment groups in the order in which they are enrolled. Blood and urine samples are taken regularly to check for toxic effects and therapeutic effectiveness. In each dosing group, 3 of 5 patients will be p24 antigen positive greater than or equal to 70 pg/ml, and 2 of 5 patients will have CDC-defined AIDS.
Eligibility:
Study Type: Interventional, Treatment, Open Label, Pharmacokinetics Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - Aerosolized pentamidine for Pneumocystis carinii pneumonia prophylaxis. - TMP/SMX as an alternative prophylactic agent, 1 DS tablet orally per day. - Acute therapy with oral acyclovir for herpes simplex infections for no more than 7 days, providing d4t is suspended Symptomatic therapy such as analgesics, antihistamines, antiemetics, antidiarrheal agents, or other supportive therapy may be administered for toxicities as deemed necessary by the principal investigator. For therapy of fever, aspirin rather than acetaminophen should be used. Concurrent Treatment: Allowed: - Transfusion of up to 2 units of packed red blood cells every 3 weeks for grade 3 or grade 4 anemia (see Recommendations for Grading of Acute and Subacute Toxic Effects (Adults)) until patient returns to baseline from grade 3 or to baseline or grade 1 from grade 4. Patient must have: - AIDS or AIDS related complex (CDC Group IVA or CDC Group IVC-2 with thrush or oral leukoplakia). - Ability to provide informed consent. - Availability to follow-up for at least 6 months. - Absence of active, AIDS-defining opportunistic infection on study entry. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: - Active, AIDS-defining opportunistic infection. - Intractable diarrhea. - History or propensity for seizure disorders requiring anticonvulsants for control. - Any other clinical condition which in the opinion of the investigator would make the patient unsuitable or unable to comply with the dosing requirements. Concurrent Medication: Excluded: - Systemic therapy with this or any other antiretroviral drug (including AL-721, ddI, ddC, interferon, immunomodulating drugs) or investigational drug. - Ribavirin. - Cytotoxic anticancer therapy. - Therapy with any agent known as a potent inducer or inhibitor of drug-metabolizing enzymes, such as rifampin or barbiturates. - Systemic maintenance or chemoprophylaxis for opportunistic infections. - Trimethoprim / sulfamethoxazole for Pneumocystis carinii infections. - Acute therapy with ketoconazole for thrush. - Neurotoxic agents listed in the protocol. Patients with the following are excluded: - Previous intolerance to zidovudine (AZT) as demonstrated by transfusion dependent anemia (transfusion required every 3 weeks or less and AZT-related depression of neutrophils to < 500 cells/mm3). - Life expectancy < 6 months. Prior Medication: Excluded: - Any other prior therapy which in the opinion of the investigator would make the patient unsuitable or unable to comply with the dosing requirements. Excluded within 2 weeks of study entry: - Therapy with any agent known as a potent inducer or inhibitor of drug-metabolizing enzymes, such as rifampin or barbiturates. Excluded within 1 month of study entry: - Systemic therapy with this or any other antiretroviral drug (including AL-721, interferon, immunomodulating drugs, ddI, ddC) or any investigational drug. Excluded within 3 months of study entry: - Ribavirin. - Cytotoxic anticancer therapy. Prior Treatment: Excluded: - Any prior therapy which in the opinion of the investigator would make the patient unsuitable or unable to comply with the dosing requirements. Preference: - Tolerating zidovudine (AZT) at time of study entry. Active alcohol or drug abuse sufficient, in the investigator's opinion, to prevent adequate compliance with study therapy.
Total Enrollment: 40
Location and Contact Information:
Overall Study Official:
HSSacks, Study Chair,
Mount Sinai Med Ctr
New York City, New York, 10029
United States
Cornell Univ Med Ctr
New York City, New York, 10021
United States
Additional Information:
Study ID Numbers: ACTG 089; AI455-002,070V3
Study Start Date:
Record last reviewed: December 1994
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000988
Other Hiv Infections Studies:
1. Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients
2. A Pilot Study of Non-Hodgkin's Lymphoma: Chemotherapy and Blood Levels of Organochlorines
3. Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study
4. Influence of the MDR1 Genotype on Blood Levels of Indinavir and Saquinavir in Healthy Volunteers
5. The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease
Related Studies:
Other HIV Infections Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
A Study of BMY-27857 in Patients with AIDS or AIDS Related Complex
|
|
|
|
|
|
|
|
